Bellerophon Therapeutics (NASDAQ:BLPH) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH) in a report issued on Monday. The brokerage issued a hold rating on the biotechnology company’s stock.

Bellerophon Therapeutics Stock Performance

NASDAQ BLPH opened at $0.04 on Monday. The company has a market capitalization of $440,388.00, a P/E ratio of -0.04 and a beta of 0.70. Bellerophon Therapeutics has a one year low of $0.03 and a one year high of $0.41. The stock has a 50 day moving average price of $0.04 and a 200-day moving average price of $0.05.

About Bellerophon Therapeutics

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.